Latigo Biotherapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
LTGO$13.35+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $401,241 | $69,437 |
| Restricted cash | 168 | 192 |
| Prepaid expenses and other current assets | 5,033 | 4,200 |
| Total current assets | 406,442 | 73,829 |
| Operating lease right-of-use assets | 1,141 | 625 |
| Property and equipment, net | 440 | 446 |
| Other assets | 433 | 616 |
| Total assets | $408,456 | $75,516 |
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $5,085 | $5,015 |
| Accrued expenses and other current liabilities | 8,174 | 12,868 |
| Operating lease liabilities, current | 705 | 563 |
| Total current liabilities | 13,964 | 18,446 |
| Operating lease liabilities, non-current | 483 | 127 |
| Other long-term liabilities | 35 | 35 |
| Total liabilities | 14,482 | 18,608 |
| Commitments and contingencies (Note 6) | ||
| Redeemable convertible preferred stock: $0.0001 par value per share, none and 264,397,134 shares authorized at September 30, 2026 and December 31, 2025, respectively; none and 41,155,082 shares issued and outstanding with aggregate liquidation preference of none and $287,899 at September 30, 2026 and December 31, 2025, respectively | — | 288,582 |
| Stockholders' equity (deficit): | ||
| Preferred stock: $0.0001 par value per share, 10,000,000 shares authorized at September 30, 2026 and none authorized at December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock: $0.0001 par value per share, 999,999,999 shares and 342,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 66,299,347 shares and 878,521 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 7 | — |
| Additional paid-in capital | 706,805 | 11,457 |
| Accumulated deficit | (312,838) | (243,131) |
| Total stockholders' equity (deficit) | 393,974 | (231,674) |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $408,456 | $75,516 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.